NMP22 is predictive of recurrence in high-risk superficial bladder cancer patients

Journal of the Canadian Urological Association

Volumn 3, Issue 6, 2009, Pages 454-458

  Lau, Paul ^a   Chin, Joseph L ^a   Pautler, Stephen ^a   Razvi, Hassan ^a   Izawa, Jonathan I ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 76749150356     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: 10.5489/cuaj.1173     Document Type: Article

References (17)

1. Canadian Cancer Society; National Cancer Institute of Canada; Statistics Canada. Canadian cancer statistics. Toronto; 2008.
2. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology 2005;66(6suppl1):4-34.
3. Pow-Sang JM, Seigne JD. Contemporary management of superficial bladder cancer. Cancer Control 2000;7(4):335-9.
4. Nickerson J. Experimental observations of a nuclear matrix. J Cell Sci 2001;114:463-74.
5. Zink D, Fischer AH, Nickerson JA. Nuclear structure in cancer cells. Nat Rev Cancer. 2004;4: 677-87.
6. Fey EG, Penman S. Nuclear matrix proteins reflect cell type of origin in cultured human cells. Proc Natl Acad Sci 1988;85:11-5.
7. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005;293:810-6.
8. Soloway MS, Briggman JV, Carpinito GA, et al. Use of a New Tumor Marker, Urinary NMP22, in the Detection of Occult or Rapidly Recurring Transitional Cell Carcinoma of the Urinary Tract Following Surgical Treatment. J Urol 1998;156:363-7.
9. Grossman HB, Soloway M, Messing E, et al. Surveillance for recurrent bladder cancer using a point-ofcare proteomic assay. JAMA 2006;295:299-305.
10. Lotan Y, Shariat SF. Impact of risk factors on the performance of the nuclear matrix protein 22 point-ofcare test for bladder cancer detection. BJU Int 2008;101:1362-7.
11. Holmang S, Hedelin H, Anderstron C, et al. The relationship among multiple recurrences, progression and prognosis of patients with Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995;153:1823-6.
12. National Comprehensive Cancer Network. Available at: http://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf. Accessed November 5, 2009.
13. Budman LI, Kassouf W, Steinberg JR. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2008;2:212-221.
14. Nguyen CT, Jones JS. Defining the role of NMP22 in bladder cancer surveillance. World J Urol 2008;26: 51-8.
15. Compton DA, Cleveland DW. NuMA is required for the proper completion of mitosis. J Cell Biol 1993;120: 947-57.
16. Taimen P, Viljamaa M, Kallajoki M. Preferential expression of NuMA in the nuclei of proliferating cells. Exp Cell Res 2000;256:140-9.
17. Sanchez-Carbayo M, Urrutia M, Gonzalez de Buitrag JM, et al. Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma. Cancer 2001;92:2820-8.